Translational and Clinical Pharmacology (TCP), the official journal of the KSCPT since 1993, publish 4 issues per year.
Translational and Clinical Pharmacology (TCP), the official journal of the KSCPT since 1993, is published on 15 of March, June, September and December.
Manuscripts are generally reviewed by at least two expert reviewers. Usually, authors will receive an editorial report within one month of receipt of the complete manuscript to the editorial office. The final decision rests with the editor of TCP. Any appeal against the editorial decision must be made within 2 weeks of the date of the decision letter. Manuscripts invited by editors can be reviewed internally by editors and/or external reviewers. Conflicts of interests of reviewers and editors as well as those of authors are to be declared for each article (See the “Principles and Policies of Transparency” of TCP)
The author is defined as the person who satisfies criteria proposed by ICMJE (International Committee of Medical Journal Editors): substantial contribution in from conception, data acquisition/analysis, drafting, revising and final approval of manuscript and agreement to be accountable for questions on the accuracy and integrity of the work. The corresponding author submitting a manuscript must ensure that all authors listed are eligible for authorship. The editors expect each author to have read the complete manuscript and to take responsibility for the content and completeness of the manuscript and to understand that if the paper, or part of the paper, is found to be faulty or fraudulent, then he/she shares responsibility with his/her coauthors. If authorship of a manuscript changes during the publication process, notification of the change, signed by the corresponding author and any authors whose names have been added to or removed from the manuscript, must be sent to the Editorial Office. A statement that certain authors have contributed equally to the work may be included as a footnote on the title page.
The corresponding author must verify that the manuscript has been approved by all authors, has not been previously reported, and will not be submitted elsewhere while under review by the TCP in the cover letter. If any preliminary or related report other than an abstract has been published or submitted, or is in consideration of publication, a copy must accompany the submission.
All benefits in any form from a commercial party related directly or indirectly to the subject of this manuscript or any of the authors must be acknowledged. For each source of funds, both the research funder and the grant number should be given. If no conflict exists, authors should state: The authors declare that they have no conflict of interest. This note should be written in the Conflict of interest section before the reference list. TCP’s policies on handling potential conflicts of interest of editors, authors, and reviewers are posted in the journal home.
The authors may submit any complaints on the editorial process including peer review, editorial decision or else to the EIC. The complaints submitted will be handled at the editorial board meeting.
All of the manuscripts should be prepared in strict observation of research and publication ethics guidelines recommended by ICMJE, and the Korean Association of Medical Journal Editors.
Manuscripts submitted for publication must contain a statement to the effect that all human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements.
TCP suggests that authors register clinical trials before the first subject is enrolled. For TCP, clinical trial is defined as any research project that prospectively assigns human subjects to a pharmacological intervention or concurrent comparison or control groups to study the cause-and-effect relationship between this intervention and a health outcome. The ICMJE policies on registration of clinical trials can be found at: http://www.icmje.org/clin_trialup.htm.
TCP does not advocate one particular registry. Appropriate registries (such as www.clinicaltrials.gov) must be (1) accessible to the public at no charge, (2) open to all prospective registrants, and (3) managed by a not-for-profit organization. There must be a mechanism to ensure the validity of the registration data, and the registry should be electronically searchable. An acceptable registry must include at minimum the data elements available at the ICMJE website listed above.
Reports of randomized, controlled trials should follow the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement. See for the current CONSORT guidelines and checklist http://www.consort-statement.org/statement/revisedstatement.htm.
The latest version of American Medical Association Manual of Style (9th edition), Stedman’s Medical Dictionary (27th edition) and Merriam-Webster’s Collegiate Dictionary (10th edition) should be used as standard references. Refer to drugs and therapeutic agents by their accepted generic or chemical name, and do not abbreviate them (a proprietary name may be given only with the first use of the generic name). Code names should be used only when a generic name is not yet available (the chemical name and a figure giving the chemical structure of the drug is required). Copyright or trade names of drugs should be capitalized and placed in parentheses after the name of the drug. Names and locations (city and state in United States; city and country outside United States) of manufacturers of drugs, supplies, or equipment cited in a manuscript are required to comply with trademark law and should be provided in parentheses.
Authors who require editing for language are encouraged to consult language editing services prior to submission.
Editorial, Commentary, Book review, Meeting report, Opinion, News etc
Review Articles / Tutorials
Review articles/tutorials on various topics are welcome. Both invited and unsolicited submissions are published. Unsolicited manuscripts will be peer-reviewed as other submissions.
PMS (postmarketing surveillance) report
The format of PMS reports is identical to that of original research articles, but the Methods section should be subdivided into Study design, Study patients, Measurements, Statistical analysis and the Results section should be subdivided into Demographic and baseline characteristics, Safety and Efficacy. The Discussion section is recommended to be less than 500 words to keep the PMS report as concise as possible.
BE (bioequivalence) report
The format of BE reports is identical to that of original research articles, but the Discussion section is recommended to be less than 500 words to keep the BE report as concise as possible.
Therapeutics Lecture is an invited review in the question and answer format. The pharmacotherapy questions are those that may be frequently asked by primary care physicians or trainees at university hospitals.
Case reports on pharmacotherapy or clinical trials are welcome. Both invited and unsolicited submissions are published. Unsolicited manuscripts will be peer-reviewed as other submissions.
Manuscripts should be submitted in MS Word.
The manuscript is to be arranged in the following order.
(a) Title page
(b) Abstract and Keywords
*Sections (c)-(f) are required for original articles only.
(j) Figure legends
The title page should include:
The abstract should be less than 250 words in an unstructured format. It should succinctly summarize contents of the manuscript.
Please provide 3 to 5 keywords which can be used for indexing purposes.
This section can be brief and should state the relevant background for and the main purposes of the study reported. Avoid review type introductions.
Methodology is the most important section of a manuscript as it determines if the results and conclusions of the study were validly derived. Methods should be concise and clear such that the study could be reproduced by another investigator.
The results should be presented in figures and tables, although some results that do not require documentation can be given solely in the text. Extensive discussion should not be given in the Results section.
The discussion should be pertinent to the results. Speculation is to be based on data only and this section should not repeat results.
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full. If there is nothing to state, this section may be omitted.
Conflict of Interest
Conflict of interest should be stated. In case there is no conflict of interests, it should also be stated.
Names of journals are abbreviated according to the List of Journals Indexed for Medline. Titles of journals not listed in Medline should be spelled out in full. References should be numbered consecutively as they appear in the text, with the numbers in square brackets on the text line (e.g., [3, 7–9, 57]). Only published works, as well as manuscripts in press, should be included in the reference list; articles that are submitted or in preparation should be referred to as “unpublished data” in the text. In the reference list, all authors should be included unless there are more than six, in which case only the first 6 authors should be listed, followed by “et al.”
The citation of journals, books, multi-author books, and articles published online should conform to the following examples:
Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, et al. Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 2009;105:731-738. doi: 10.1007/s00421-008-0955-8.
Pittet D, Wenzel RP. Nosocomial bloodstream in¬fections: secular trends in rates, mortality, and con-tribution to total hospital deaths. Arch Intern Med 1995;155:1177-1184.
Shon JH, Kim N, Park SJ, Oh MK, Kim EY, Lee SH, et al. Effect of Renal Impairment and Hemodialysis on the Pharmacokinetics of Gemigliptin (LC15-0444). Diabetes Obes Metab 2014 [In Press]
Article by DOI
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med 2000 doi:10.1007/s001090000086
Brown B, Aaron M. The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd ed. Wiley, New York, 2001;230-257
Why participate? http://www.parexel.com/company/volunteer/why-participate/ Accessed 25 March 2014
Trent JW. Experimental acute renal failure. Dissertation, University of California, 1975
Tables with their titles should be double-spaced, each on a separate sheet, with an explanatory title and sufficient experimental detail in the accompanying legend so as to be intelligible without reference to the text. Do not duplicate data by presenting it both in the text and in a table or figure. Footnotes to tables should be indicated by superscript symbols or lower-case letters and included beneath the table body. Data in the text should not be repeated extensively in tables or figures.
Legends should be concise. However, the legend should include sufficient detail to make them intelligible without reference to the text, should define all labels and symbols used in the figure art, and should provide other essential information such as magnification or scale bar dimension.
Each figure accompanied by a label (e.g., Fig. 1) should be submitted in JPEG format with resolution of 600 dpi and 3 mega pixels or higher as well as included in the manuscript document. The title should be part of the legend and not lettered onto the figure itself. Data in the text should not be repeated extensively in tables or figures.